Boston Scientific (BSX)
104.17
+4.27 (4.27%)
NYSE · Last Trade: Oct 22nd, 2:06 PM EDT
Detailed Quote
Previous Close | 99.90 |
---|---|
Open | 103.10 |
Bid | 104.14 |
Ask | 104.19 |
Day's Range | 101.52 - 105.00 |
52 Week Range | 80.64 - 109.50 |
Volume | 11,460,332 |
Market Cap | 148.32B |
PE Ratio (TTM) | 62.00 |
EPS (TTM) | 1.7 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 10,102,599 |
Chart
About Boston Scientific (BSX)
Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
News & Press Releases
Shares of medical device company Boston Scientific (NYSE:BSX)
jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised its full-year financial outlook.
Via StockStory · October 22, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · October 22, 2025
Goldman Sachs analyst David Roman reiterated a Buy rating and $120 price target for Boston Scientific after strong Q3 results and raised guidance.
Via Benzinga · October 22, 2025
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
Via MarketMinute · October 22, 2025
Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533Mstocktwits.com
Via Stocktwits · October 17, 2025
Boston Scientific Q3 revenue hit $5.07 billion, beating forecasts. The company raised its full-year guidance based on strong segment growth.
Via Benzinga · October 22, 2025
Boston Scientific stock jumped early Wednesday on a strong 2025 outlook following its third-quarter sales and earnings beat.
Via Investor's Business Daily · October 22, 2025
The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.
Via MarketBeat · October 22, 2025
Medical device company Boston Scientific (NYSE:BSX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.
Via StockStory · October 22, 2025
Boston Scientific beats Q3 2025 earnings and revenue forecasts, reporting strong sales growth and issuing optimistic Q4 guidance.
Via Chartmill · October 22, 2025
Medical device company Boston Scientific (NYSE:BSX)
will be announcing earnings results this Wednesday morning. Here’s what to expect.
Via StockStory · October 20, 2025
Via Benzinga · October 17, 2025
Boston Scientific Corp (NYSE: BSX) to acquire Nalu Medical Inc. for $600 million in cash. Deal expected to close in first half of 2026.
Via Benzinga · October 17, 2025
Via Benzinga · October 15, 2025
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via StockStory · October 14, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · October 8, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · October 6, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Via Chartmill · October 1, 2025
Via Benzinga · October 1, 2025
Across the recent three months, 12 analysts have shared their insights on Boston Scientific (NYSE: BSX), expressing a variety of opinions spanning from bullish to bearish.
Via Benzinga · September 29, 2025